Extended use dexamethasone-associated posterior reversible encephalopathy syndrome with cisplatin-based chemotherapy

Journal of Clinical Neuroscience

Volumn 16, Issue 12, 2009, Pages 1688-1690

  Nguyen, MyChau T ^a   Virk, Irim Y ^a   Chew, Lita ^a   Villano, J Lee ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Cisplatin; Dexamethasone; Encephalopathy; Posterior reversible encephalopathy syndrome (PRES)

Indexed keywords

APREPITANT; CISPLATIN; DEXAMETHASONE; DIAZEPAM; DIPHENHYDRAMINE; DRONABINOL; FOSPHENYTOIN SODIUM; LORAZEPAM; MAGNESIUM; MELPHALAN; ONDANSETRON; PACLITAXEL; PALONOSETRON; PEMETREXED; POTASSIUM; PROCHLORPERAZINE; SODIUM;

ADULT; ADVANCED CANCER; ARTICLE; ASCITES; ATTENUATION; BRAIN DISEASE; CANCER CHEMOTHERAPY; CASE REPORT; COGNITIVE DEFECT; CYTOREDUCTIVE SURGERY; DIZZINESS; DRUG DOSE REDUCTION; ELECTROENCEPHALOGRAM; FEMALE; HEMISPHERE; HERNIOPLASTY; HUMAN; HYPOTHESIS; INTRAPERITONEAL MESOTHELIOMA; LYMPHADENOPATHY; MAGNESIUM BLOOD LEVEL; MESOTHELIOMA; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SEIZURE; SODIUM BLOOD LEVEL; VOMITING; WHITE MATTER;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; CISPLATIN; DEXAMETHASONE; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; NAUSEA; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME;

EID: 70350714230     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2009.05.012     Document Type: Article

References (21)

1. Balis F.M., Lester C.M., Chrousos G.P., et al. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol 5 (1987) 202-207
2. Irvin W., MacDonald G., Smith J.K., et al. Dexamethasone-induced posterior reversible encephalopathy syndrome. J Clin Oncol 25 (2007) 2484-2486
3. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
4. Hinchey J., Chaves C., Appignani B., et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334 (1996) 494-500
5. Stott V.L., Hurrell M.A., and Anderson T.J. Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed. Int Med J 35 (2005) 83-90
6. Filley C.M., and Kleinschmidt-DeMasters B.K. Toxic leukoencephalopathy. N Engl J Med 345 (2001) 425-432
7. Belgaumi A.F., Al-Bakrah M., Al-Mahr M., et al. Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin. Cancer 97 (2003) 2898-2903
8. Sterzing F., Grehn C., Dinkel J., et al. Severe reversible toxic encephalopathy induced by cisplatin in a patient with cervical carcinoma receiving combined radiochemotherapy. Strahlenther Onkol 183 (2007) 487-489
9. Pandey R., Patel A., Shah S., et al. A rare complication in a case of multiple myeloma on therapy with thalidomide and dexamethasone-reversible posterior lobe leukoencephalopathy. Leuk Lymphoma 47 (2006) 1431-1434
10. Ito Y., Arahata Y., Goto Y., et al. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol 19 (1998) 415-417
11. Steeghs N., de Jongh F.E., Sillevis Smitt P.A., et al. Cisplatin-induced encephalopathy and seizures. Anticancer Drugs 14 (2003) 443-446
12. Sueblinvong T., Noophun P., Pataradool K., et al. Posterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary. J Obstet Gynaecol Res 28 (2002) 99-103
13. Noda K., Nishiwaki Y., Kawahara M., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 (2002) 85-91
14. Grossman H.B., Natale R.B., Tangen C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349 (2003) 859-866
15. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 (2004) 1945-1952
16. Winton T., Livingston R., Johnson D., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352 (2005) 2589-2597
17. Posner M.R., Hershock D.M., Blajman C.R., et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357 (2007) 1705-1715
18. Vermorken J.B., Remenar E., van Herpen C., et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357 (2007) 1695-1704
19. Mead G.M., Arnold A.M., Green J.A., et al. Epileptic seizures associated with cisplatin administration. Cancer Treat Rep 66 (1982) 1719-1722
20. Stewart D.J., Maroun J.A., Laframboise G., et al. Cisplatin plus cytosine arabinoside in the treatment of squamous cell carcinoma of the head and neck. Am J Clin Oncol 9 (1986) 200-203
21. Lindeman G., Kefford R., Stuart-Harris R., et al. Cisplatin neurotoxicity. N Engl J Med 323 (1990) 64-65